Search results
- Regulatory news (469) Apply Regulatory news filter
- Press releases (251) Apply Press releases filter
- Basic page (62) Apply Basic page filter
- Corporate presentations (31) Apply Corporate presentations filter
- Pipeline (29) Apply Pipeline filter
- Shareholder meeting (25) Apply Shareholder meeting filter
- Team member (23) Apply Team member filter
- Videos (16) Apply Videos filter
- Webcasts and audio (15) Apply Webcasts and audio filter
- Financial reports (13) Apply Financial reports filter
- Analyst (12) Apply Analyst filter
- Event (5) Apply Event filter
- Investor contact (5) Apply Investor contact filter
- Research (3) Apply Research filter
- Financial calendar (1) Apply Financial calendar filter
- Webform (1) Apply Webform filter
Oxford BioMedica notes the sBLA submission to FDA for Kymriah™ in adult patients with r/r DLBCL
Oxford, UK – 31 October 2017: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy